Allo-SCT regimens
| . | No. (no. of TCDs) . | % . |
|---|---|---|
| MAC regimens* | 25 (6) | 74 |
| TBI ≥ 10 Gy + Cy | 17 (3) | 50 |
| Bu ≥ 10 mg/kg + Cy ± Mel ± Flu | 5 (3) | 15 |
| Bu ≥ 10 mg/kg + Flu ± thiotepa | 3 (0) | 9 |
| RIC regimens | 9 (5) | 26 |
| Bu ≤ 6 mg/kg + Flu ± thiotepa ± Cy | 5 (4) | 15 |
| TBI 2 Gy + Flu + Cy | 2 (0) | 6 |
| TBI 2 Gy + Flu + AraC | 1 (0) | 2,5 |
| Flu + treosulfan | 1 (1) | 2,5 |
| . | No. (no. of TCDs) . | % . |
|---|---|---|
| MAC regimens* | 25 (6) | 74 |
| TBI ≥ 10 Gy + Cy | 17 (3) | 50 |
| Bu ≥ 10 mg/kg + Cy ± Mel ± Flu | 5 (3) | 15 |
| Bu ≥ 10 mg/kg + Flu ± thiotepa | 3 (0) | 9 |
| RIC regimens | 9 (5) | 26 |
| Bu ≤ 6 mg/kg + Flu ± thiotepa ± Cy | 5 (4) | 15 |
| TBI 2 Gy + Flu + Cy | 2 (0) | 6 |
| TBI 2 Gy + Flu + AraC | 1 (0) | 2,5 |
| Flu + treosulfan | 1 (1) | 2,5 |
AraC indicates cytosine arabinoside; Bu, busulfan; Cy, cyclophosphamide; Flu, fludarabine; Mel, melphalan; TBI, total body irradiation; and TCDs, T-cell depletions.
Doses for the MAC regimens are provided in “Methods.”